Key facts
Reacts with:Human,
Target:CD47See target data
Product details:
Inhibitory Immune Checkpoint panel 2 - Human IHC
ab278173
contains multiple trial-sized versions of anti-human antibody clones against CD47, SIRP alpha, CD272/BTLA, galectin 9/Gal-9, Indoleamine 2, 3-dioxygenase, 2B4 and CD276. For guidelines on how to use each antibody within the panel, please consult the individual datasheet for each antibody.specifically selected for high performance in various applications. They are provided as a sampler panel to allow you to easily evaluate each antibody.
Panel contains:
- Rabbit monoclonal [EPR21794] to CD47 (20 μL)
ab218810
- Rabbit monoclonal [EPR22930-163] to SIRP alpha (20 μL)
ab260039
- Rabbit monoclonal [EPR22224-271] to CD272/BTLA (20 μL)
ab230976
- Rabbit monoclonal [EPR22214] to galectin 9/Gal-9 (20 μL)
ab227046
- Rabbit monoclonal [EPR20374] to Indoleamine 2, 3-dioxygenase (20 μL)
ab211017
- Rabbit monoclonal [EPR23692-33] to 2B4 (20 μL)
ab256370
- Rabbit monoclonal [SP206] to CD276 (20 μL)
ab227670
Explore our range of antibody sample panels designed to provide you with a variety of trial-size antibodies in a convenient and cost-effective format.
Carrier-free formulations of our recombinant antibodies are also available for easy conjugation to labels of your choice and for multiplex applications. Use our intuitive search and select carrier-free or your label of choice. For bespoke conjugations or large volumes email
[email protected].
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD47 also known as integrin-associated protein is a transmembrane protein with a molecular mass of approximately 50 kDa. This target is found on a wide variety of cells and tissues including red blood cells and endothelial cells. CD47 interacts with signal regulatory protein alpha (SIRP alpha) on macrophages creating a 'don't eat me' signal that helps the cell avoid phagocytosis. Indoleamine 23-dioxygenase (IDO) is an enzyme involved in tryptophan metabolism with a mass around 45 kDa expressed in dendritic cells and monocytes. 2B4 also called CD244 is a cell surface receptor on natural killer (NK) cells and some T cells. Galectin-9 (Gal-9) primarily found in immune tissues plays a role in modulating immune responses. CD272 or BTLA (B and T Lymphocyte Attenuator) is a receptor involved in immune regulation expressed on T cells while CD276 also known as B7-H3 is a member of the B7 family expressed on antigen-presenting cells (APCs).
Biological function summary
CD47 plays a role in cell survival by inhibiting macrophage-mediated phagocytosis through its interaction with SIRP alpha. This interaction is important in maintaining the balance between cell preservation and immune clearance. IDO contributes to immune tolerance by catabolizing tryptophan reducing its availability and modulating T cell function. 2B4 part of the SLAM family functions in activating NK cells while Gal-9 regulates T cell apoptosis and inflammation. BTLA acts as an inhibitory receptor during T cell activation often engaging with CD276 in immunosuppressive contexts. Most targets do not exist in isolation; rather they function within complexes that facilitate their biological roles.
Pathways
CD47-SIRP alpha signaling integrates into the immune evasion pathways by preventing phagocytosis a cellular immune mechanism. This pathway includes other molecules like SHP-1 and SHP-2 which transduce inhibitory signals within phagocytic cells. IDO is part of the kynurenine pathway of tryptophan metabolism influencing immune regulation by modulating the local immune environment. Alongside IDO other molecules such as kynurenine can impact T cell proliferation and function. 2B4 fits within the NK cell activation pathway interacting with its ligand CD48. BTLA often associated with CD276 connects to pathways involved in immune checkpoint signaling influencing T cell responses.
CD47 overexpression has links to cancer as tumors exploit the 'don't eat me' signal to evade immune detection. Its relationship with SIRP alpha positions it as a therapeutic target in oncology. IDO expression can contribute to tumor immune escape by modulating the tumor microenvironment and its role in tryptophan metabolism connects it uniquely to cancer immunotherapy. Gal-9 plays a part in autoimmune diseases by regulating inflammation and T cell death. BTLA through its regulatory role has associations with autoimmune disorders influencing how the immune system responds to self-antigens. Understanding these targets enriches therapeutic development strategies by examining how they interconnect with diseases and other proteins.
